| Q55456735 | 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. |
| Q47136071 | A 4-miRNA signature to predict survival in glioblastomas |
| Q91991768 | A Nomogram for Predicting Individual Prognosis of Patients with Low-Grade Glioma |
| Q89724165 | A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level |
| Q98630856 | A novel image signature-based radiomics method to achieve precise diagnosis and prognostic stratification of gliomas |
| Q90273455 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol |
| Q58706639 | A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey |
| Q89561636 | A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort |
| Q92541791 | Ability of Radiomics in Differentiation of Anaplastic Oligodendroglioma From Atypical Low-Grade Oligodendroglioma Using Machine-Learning Approach |
| Q91576664 | Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma |
| Q64091408 | Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status |
| Q91942754 | Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography |
| Q90986735 | Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial |
| Q91789098 | Bit1 Silencing Enhances the Proliferation, Migration, and Invasion of Glioma Cells Through Activation of the IL-6/STAT3 Pathway |
| Q63386970 | Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG |
| Q64946311 | Cell lines and immune classification of glioblastoma define patient's prognosis. |
| Q92446720 | Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network |
| Q47096286 | Circadian Alterations in a Murine Model of Hypothalamic Glioma |
| Q90157680 | Clinical nomogram for predicting the survival of patients with cerebral anaplastic gliomas |
| Q64115476 | Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era |
| Q58802044 | Comparisons of the accuracy of radiation diagnostic modalities in brain tumor: A nonrandomized, nonexperimental, cross-sectional trial |
| Q90755623 | Correlation of Dynamic O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography, Conventional Magnetic Resonance Imaging, and Whole-Brain Histopathology in a Pretreated Glioblastoma: A Postmortem Study |
| Q90654936 | Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q49317056 | Current therapeutic approaches to diffuse grade II and III gliomas. |
| Q64099174 | Decoding the Interdependence of Multiparametric Magnetic Resonance Imaging to Reveal Patient Subgroups Correlated with Survivals |
| Q89629807 | Deep Convolutional Radiomic Features on Diffusion Tensor Images for Classification of Glioma Grades |
| Q92424608 | Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis |
| Q89559170 | Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma |
| Q91847771 | Does Surveillance-Detected Disease Progression Yield Superior Patient Outcomes in High-Grade Glioma? |
| Q90103140 | Drosophila melanogaster as a Model System for Human Glioblastomas |
| Q89076261 | Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas |
| Q104135046 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood |
| Q91878200 | Educational Case: Histologic and Molecular Features of Diffuse Gliomas |
| Q90378478 | Effect of a Time Delay for Concomitant Chemoradiation After Surgery for Newly Diagnosed Glioblastoma: A Single-Institution Study with Subgroup Analysis According to the Extent of Tumor Resection |
| Q55456779 | Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. |
| Q48172740 | Evidence-based management of adult patients with diffuse glioma - Authors' reply |
| Q55457830 | Evidence-based management of adult patients with diffuse glioma. |
| Q92273332 | Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas |
| Q89602658 | Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma |
| Q57457153 | FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma |
| Q92336270 | Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment |
| Q93048647 | Fluorescein Application in Cranial and Spinal Tumors Enhancing at Preoperative MRI and Operated With a Dedicated Filter on the Surgical Microscope: Preliminary Results in 279 Patients Enrolled in the FLUOCERTUM Prospective Study |
| Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
| Q64234325 | German Cancer Consortium (DKTK) - A national consortium for translational cancer research |
| Q90734706 | Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets |
| Q64113592 | Glioblastoma in Elderly Patients: Current Management and Future Perspectives |
| Q47827482 | Glioblastoma in elderly patients: solid conclusions built on shifting sand? |
| Q58609492 | Harnessing the immune system in glioblastoma |
| Q89931191 | Heme Oxygenase-1 and Carbon Monoxide Regulate Growth and Progression in Glioblastoma Cells |
| Q92604181 | High dose vs low dose irradiation of the subventricular zone in patients with glioblastoma-a systematic review and meta-analysis |
| Q90292021 | How I treat anaplastic glioma without 1p/19q codeletion |
| Q91812608 | How we treat glioblastoma |
| Q94684157 | How we treat patients with brain tumour during the COVID-19 pandemic |
| Q92989611 | Hyperbaric Oxygen for Radiation Necrosis of the Brain |
| Q57826827 | Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience |
| Q55456947 | IDH-mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas. |
| Q55363441 | IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. |
| Q98205193 | ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma |
| Q89561650 | Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults |
| Q57176630 | Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging |
| Q60959909 | Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend |
| Q92341936 | Immunotherapy for glioblastoma: quo vadis? |
| Q57299883 | Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule |
| Q97543197 | Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity |
| Q90697924 | Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02 |
| Q55457436 | Is it all a matter of size? Impact of maximization of surgical resection in cerebral tumors. |
| Q64924335 | Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. |
| Q64076906 | Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival |
| Q91857089 | Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors |
| Q90730874 | Lymphatic outflow of cerebrospinal fluid is reduced in glioma |
| Q90169778 | MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas |
| Q47847472 | Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. |
| Q64899756 | MicroRNA based theranostics for brain cancer: basic principles. |
| Q89489899 | Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors |
| Q89163281 | Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach |
| Q97543564 | Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma |
| Q53077438 | Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. |
| Q52570231 | Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. |
| Q97538395 | Multivariate analysis reveals differentially expressed genes among distinct subtypes of diffuse astrocytic gliomas: diagnostic implications |
| Q57060417 | N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma |
| Q55457074 | NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-κB p65 signals. |
| Q88733057 | Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging |
| Q48238113 | Nucleolar and spindle-associated protein 1 is a tumor grade correlated prognosis marker for glioma patients. |
| Q90247587 | Oligodendroglioma confers higher risk of radiation necrosis |
| Q58708128 | PR-LncRNA signature regulates glioma cell activity through expression of SOX factors |
| Q92892697 | Perioperative fatigue in patients with diffuse glioma |
| Q90598882 | Predicting Glioblastoma Recurrence from Preoperative MR Scans Using Fractional-Anisotropy Maps with Free-Water Suppression |
| Q58762013 | Predicting IDH genotype in gliomas using FET PET radiomics |
| Q61813703 | Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone |
| Q90643353 | Primary brain tumours in adults |
| Q55042008 | Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation. |
| Q49989559 | Prognostic Factors in Glioblastoma: Is There a Role for Epilepsy? |
| Q94340451 | Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide |
| Q47265360 | Protein Kinase A Distribution Differentiates Human Glioblastoma from Brain Tissue |
| Q90682701 | Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy |
| Q90265004 | Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO) |
| Q55457442 | Reaching the Edge of Diffuse Gliomas: Are We There Yet? |
| Q49505406 | Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. |
| Q90746646 | Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET) |
| Q88483360 | Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas |
| Q64889096 | Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity. |
| Q64935839 | Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. |
| Q90179850 | Repeat Resection and Intraoperative Radiotherapy for Malignant Gliomas of the Brain: A History and Review of Current Techniques |
| Q89927568 | Resting-state fMRI Detects Alterations in Whole Brain Connectivity Related to Tumor Biology in Glioma Patients |
| Q91810386 | RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas |
| Q90331608 | Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study |
| Q97643337 | Robust performance of deep learning for distinguishing glioblastoma from single brain metastasis using radiomic features: model development and validation |
| Q89605003 | Role of Infiltrating Microglia/Macrophages in Glioma |
| Q48147847 | SEOM clinical guidelines for anaplastic gliomas (2017). |
| Q58760293 | Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome |
| Q89738586 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma |
| Q58750320 | Supportive Care Needs in Glioma Patients and Their Caregivers in Clinical Practice: Results of a Multicenter Cross-Sectional Study |
| Q64065428 | Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells |
| Q52090734 | Surgery for patients with 'lower grade' glioma: putting assumptions, beliefs and convictions into perspective. |
| Q52646035 | Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs). |
| Q90055025 | Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature |
| Q38606106 | Textural features of dynamic contrast-enhanced MRI derived model-free and model-based parameter maps in glioma grading |
| Q47316880 | The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. |
| Q89622383 | The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas |
| Q55456815 | The Treatment of Gliomas in Adulthood. |
| Q57291639 | The subventricular zone concept: ready for therapeutic implications? |
| Q64114259 | The surgical perspective in precision treatment of diffuse gliomas |
| Q64965627 | Tissue-type mapping of gliomas. |
| Q57174802 | Treatment of glioblastoma in adults |
| Q100995148 | Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma |
| Q64911604 | Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. |
| Q55457266 | [Basic principles of diagnosis and treatment of gliomas]. |